Schering-Plough buys out China joint venture
This article was originally published in Scrip
Schering-Ploughhas fully acquired its former joint venture operation in China in a bid to better position itself for growth in what it already views as an important market.
You may also be interested in...
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, world-first nods for the country’s second HIF-PH inhibitor and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.
Join us for a quick audio roundup of five useful things to know from Scrip’s recent coverage of the global biopharmaceutical industry.